DelveInsight’s "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast–2034" report delivers an in-depth understanding of synovial sarcoma, historical and forecasted epidemiology as well as the synovial sarcoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Synovial Sarcoma Market with DelveInsight's In-Depth Report @ Synovial Sarcoma Market Size
Key Takeaways from the Synovial Sarcoma Market Report
- Among the 7MM, the US accounted for the highest incident cases of synovial sarcoma in 2023, with around 650 cases; these cases are expected to increase during the forecast period.
- In 2023, the total number of incident cases of synovial sarcoma in EU4 and the UK was highest in Germany, while the lowest number of cases was in Spain.
- In cases of gender-specific synovial sarcoma, males are observed to be the predominant contributors compared to females.
- As per DelveInsight’s estimates, the highest incidence of Synovial Sarcoma in Japan is in Stage II which has ~100 cases in 2023 that are projected to increase during the forecast period.
- The leading Synovial Sarcoma Companies such as Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc., and others.
- Promising Synovial Sarcoma Pipeline Therapies such as CFT8634, FHD-609, Afamitresgene autoleucel, AL3818, Itacitinib, CAB-AXL-ADC, TP-1287, APX005M, Tazemetostat, and others.
Navigate the complexities of the Synovial Sarcoma Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Synovial Sarcoma Market Forecast. Click here to get more insights @ Synovial Sarcoma Treatment Market
Synovial Sarcoma Epidemiology Segmentation in the 7MM
- total Synovial Sarcoma Incident cases
- Synovial Sarcoma Gender-specific cases
- Synovial Sarcoma Age-specific cases
- Synovial Sarcoma Location-specific cases
- Synovial Sarcoma Stage-specific cases
- Synovial Sarcoma Antigen-specific (MAGE-A4, NY-ESO-1, PRAME, and others) cases
- Synovial Sarcoma line-wise treated patient pool
Download the report to understand which factors are driving Synovial Sarcoma epidemiology trends @ Synovial Sarcoma Prevalence
Synovial Sarcoma Marketed Drugs
- TECELRA (afamitresgene autoleucel): Adaptimmune Therapeutics
TECELRA (afami-cel; formerly ADP-A2M4) is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. In August 2024, Adaptimmune Therapeutics received the US FDA accelerated approval of TECELRA for the treatment of adults with unresectable or metastatic synovial sarcoma. The approval of TECELRA was based on results of the SPEARHEAD-1 (Cohort 1) trial. TECELRA treatment resulted in an ORR of 43% with a complete response rate of 4.5%. TECELRA is the first engineered cell therapy for solid tumors. Also, it is the first new treatment option for synovial sarcoma in more than a decade. Sarcoma centers of excellence across the Unites States are being onboarded as Authorized Treatment Centers (ATCs) for TECELRA.
Synovial Sarcoma Emerging Drugs
- Letetresgene autoleucel (lete-cel): Adaptimmune Therapeutics
Letetresgene autoleucel is an engineered TCR T-cell therapy targeting the solid tumor antigen NY-ESO-1. Lete-cel is being investigated for the treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO (NCT03967223) trial in patients who received prior anthracycline treatment. Sponsorship of the ongoing clinical trials for lete-cel has transitioned from GSK to Adaptimmune. The IGNYTE-ESO trial, which is ongoing but no longer open for new participants, has had its interim analysis data presented at CTOS in 2023 also reported data for sub-study 1 of the IGNYTE-ESO trial which explores lete-cel in the first-line setting for treatment naïve patients with metastatic or unresectable synovial sarcoma or MRCLS. The company plans to launch lete-cel commercially in the US by 2026. This will be the second product in the sarcoma portfolio, targeting both synovial sarcoma and MRCLS, thereby significantly broadening treatment options for these cancers.
- AL3818 (anlotinib): Advenchen Laboratories
AL3818 is an orally administered receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFR1, VEGFR2/KDR, and VEGFR3), stem cell factor receptor (C-kit), platelet-derived growth factor (PDGFβ), and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3). AL3818 is being evaluated for the treatment of alveolar soft part sarcoma, leiomyosarcoma, and synovial sarcoma in a global Phase III trial. It is being developed by Advenchen Laboratories. The FDA and EMA granted AL3818 an orphan drug designation for the potential treatment of soft tissue sarcomas.
Get In-Depth Knowledge on Synovial Sarcoma Market Trends and Forecasts with DelveInsight @ Synovial Sarcoma Treatment Market
Synovial Sarcoma Market Outlook
Surgery remains the primary and only curative treatment for localized, resectable soft tissue sarcomas (STS), including synovial sarcoma, typically combined with radiotherapy. In terms of pharmacological therapies, which are the focus of market forecasts by DelveInsight, chemotherapy is the mainstay for metastatic sarcomas. For synovial sarcoma, the standard approach involves a fixed number of chemotherapy cycles with doxorubicin and ifosfamide as the first-line drugs, generating significant revenue in this field. YONDELIS, an antitumor agent, is approved in Europe for advanced soft tissue sarcoma after failure of standard therapies or in patients unable to receive them. However, its effectiveness for synovial sarcoma in the US remains uncertain. VOTRIENT, an oral multi-target tyrosine kinase inhibitor, is currently the only TKI approved for various STS subtypes, including synovial sarcoma. It works by inhibiting VEGFR-mediated angiogenesis and blocking receptor tyrosine kinases involved in tumor growth.
Synovial Sarcoma Treatment Market Landscape
The treatment plan for synovial sarcoma is tailored to the individual patient. The type of treatment that is usually depend on size and location of the tumor, the patient’s age and overall health, and patient’s preference. The goal of the treatment for synovial sarcoma is to cure the cancer. However, not all patients are cured. In some may come back. If the cancer comes back, it may be treated with surgery, radiation therapy, chemotherapy, or targeted therapy. As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response. Doxorubicin and Ifosfamideconstitute the first line approach thereby helping generate a large chunk of the revenue.
Gain a strategic edge in the Synovial Sarcoma Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Synovial Sarcoma Market Forecast. Click here to lead in advancements @ Synovial Sarcoma Clinical Trials Assessment
Scope of the Synovial Sarcoma Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Synovial Sarcoma Companies- Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc., and others.
- Synovial Sarcoma Pipeline Therapies- CFT8634, FHD-609, Afamitresgene autoleucel, AL3818, Itacitinib, CAB-AXL-ADC, TP-1287, APX005M, Tazemetostat, and others.
- Synovial Sarcoma Market Dynamics: Synovial Sarcoma Market Drivers and Barriers
- Synovial Sarcoma Therapeutic Assessment: Synovial Sarcoma Current marketed and Synovial Sarcoma Emerging Therapies
Table of Content
1. Key Insights
2. Synovial Sarcoma Executive Summary
3. Competitive Intelligence Analysis for Synovial Sarcoma
4. Synovial Sarcoma: Market Overview at a Glance
5. Synovial Sarcoma: Disease Background and Overview
6. Synovial Sarcoma Patient Journey
7. Synovial Sarcoma Epidemiology and Patient Population
8. Synovial Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Synovial Sarcoma Unmet Needs
10. Key Endpoints of Synovial Sarcoma Treatment
11. Synovial Sarcoma Marketed Products
12. Synovial Sarcoma Emerging Therapies
13. Synovial Sarcoma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Synovial Sarcoma Market Outlook
16. Synovial Sarcoma Market Access and Reimbursement Overview of Synovial Sarcoma
17. Synovial Sarcoma KOL Views
18. Synovial Sarcoma Market Drivers
19. Synovial Sarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
